We determined whether disulfide-linked insulin peptides that are immunogenic in vitro for CD4+ T cells bind to major histocompatibility complex class II in vivo.
Naturally processed linear antigenic peptides of 13-25 aa bind to major histocompatibility complex (MHC) class II molecules on B-cell antigen-presenting cells (APCs) (1) (2) (3) . We previously demonstrated that heterodimeric disulfidelinked insulin peptides are presented by B cells to CD4+ T cells in vitro (4) (5) (6) . Since this suggested that a disulfide-linked peptide binds to MHC class II, we analyzed whether human insulin (HI) is processed into a disulfide-linked peptide that binds to MHC class II in vivo. We investigated whether the same or different disulfide-linked HI peptides are bound to MHC class II on different thymic APCs. This was of interest, since it was proposed that thymic epithelial cells (TNCs) and dendritic cells (DCs) express a different array of MHC class II-bound antigenic peptides and mediate positive and negative T-cell selection, respectively (7) . Our data show that naturally processed heterodimeric disulfide-linked HI peptides can be eluted from MHC class II on TNCs but not DCs. They also indicate that T-cell selection may be influenced by the processing of an antigen into different MHC class IIbound peptides by different thymic APCs.
MATERIALS AND METHODS
Recombinant HI (rHI) purified from Escherichia coli K-12 strain CA7233 transformed with plasmid plac 9/4 PI ( Fig. 1A ) was radiolabeled (-3 mCi/mmol; 1 Ci = 37 GBq) at 19 distinct amino acids (Fig. 1B) (8) . Labeled rHI was indistinguishable from commercially available HI (8) and was injected into 4-to 6-week-old female BALB/c (H-2d) mice.
Cortical epithelial cells (thymic nurse cells; TNCs), corticomedullary DC rosettes (T-ROS), and a separate MHC class III medullary DC/macrophage (MO) population were isolated (9) . The DC/M4 population was recovered as lowdensity cells (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) . Remaining tissue fragments were digested with collagenase type XI (0.5 mg/ml, from Clostridium histolytum; Sigma) to obtain T-ROS and with 0.02% trypsin (0.5 ml per thymus; Sigma) in Hanks' balanced salt solution (HBSS) containing DNase I (8 pug/ml; Sigma) to purify TNCs. Before assay, TNCs were allowed to reexpress surface MHC class II during culture (16 hr, 370C) in RPMI 1640 (GIBCO) containing 10 mM Hepes (pH 7.4), 2 mM L-glutamine, 50 AuM 2-mercaptoethanol, penicillin (100 units/ ml), streptomycin (100 pg/ml), and 5% (vol/vol) fetal calf serum (CRPMI) and supplemented with interleukin 2 (IL-2; 15 units/ml).
APC yields (per mouse) were 4.2 x 104 for DCs/Mos, 1.4 x 105 for T-ROS, and 3.5 x 104 for TNCs. Enrichment of APCs was assessed by immunofluorescence using the anti-I-Ad MK-D6 (10), J1lD and 33D1 (both detect thymic DCs) (11) , anti-CD4 GK 1.5 (12) , or anti-CD8 53-6.62 (13) (14) .
Noncovalently linked membrane-associated peptides were acid eluted (15 min, 4°C; HBSS at pH 3.6) from thymic APCs and resolved by reversed-phase C18 HPLC (15) . Intracellular peptides were extracted from the acid-treated cell pellet, passed through Sephadex G-50 to obtain "insulin-sized peaks," and analyzed by C18 HPLC (15 Fig. 1B ) and 5 min later with labeled rHI (2 pg, -2.2 x 106 cpm). About 30% of the rHI-associated radioactivity localized to the thymus by 2 min postinjection and decreased rapidly thereafter. Ifpreinjection of HI B23-B30 was omitted, only 3% of the rHI-associated radioactivity localized to the thymus. Since HI B23-B30 contains residues that bind to the HI receptor (22) , it may inhibit HI-HI receptor interactions on hepatocytes and adipocytes and enhance the routing of rHI to the thymus.
TNCs and DCs/M~s were isolated from 12 BALB/c mice injected with labeled rHI. Although it takes only 2 min for labeled rHI to reach the thymus after i.v. injection, another 30 min to 1 hr at 23°C is required to isolate these APCs during which more internalization and processing of HI can occur. Thus, thymic APC-derived HI peptides were characterized -1 hr after injection. About 25% of the rHI-associated radioactivity in the thymus was in TNCs, and about half of this activity was equally distributed between the plasma membrane and intracellular compartments. A similar amount (32%) and distribution of the rHI-associated radioactivity was found in DCs/M4s.
Membrane-associated and intracellular peptides in -5-6 x 106 thymic TNCs and DCs/M~s were resolved by C18 HPLC. Since peptides were not detectable by their OD214, we monitored HI peptide-associated radioactivity. A partial overlap was observed for the intracellular and membrane peptides from each APC (Fig. 1C) . Six distinct membraneassociated peptides were found on TNCs and DCs/Mis, and only one peptide (fraction 15) was common to each profile. Amino acid analyses showed that some intracellular (Al-A12/B7-B23) and membrane (A4-A12/B7-B23) TNC peptides contain A-loop residues disulfide-linked to B-chain residues (Fig. 1C Upper) . These peptides were not detected on DCs/M4s (Fig. 1C Lower) . Rather, some DC/M4 peptides consist of C-terminal A-chain residues A20 and A21 disulfide-linked to core B-chain residues, and such peptides are not immunogenic (4, 22 2A ). This peak was absent from precipitated DC/MO samples (Fig. 2B) . Thus, rHI is processed in vivo into peptides that bind to MHC class II on TNCs but not DCs/M~s.
Two I-Ad-bound rHI peptides on TNCs were resolved by HPLC at fractions 15 and 25 (Fig. 2C) . Amino acid analyses established that they contain residues A6-A11 and B7-B19 (fraction 15) and A19-A21 and B14-B21 (fraction 25). The synthetic HI peptides A6-All, B7-B19, A19-A21, and B14-B21 each elute in different fractions from C18 (data not shown). Moreover, the synthetic disulfide-linked peptides A6-All/B7-B19 and A19-A21/B14-B21 coelute with the radiolabeled HI peptides in fractions 15 and 25, respectively. Although two peptides that coelute from C18 may differ in structure, these observations indicate that the two HI peptides eluted from I-Ad are the disulfide-linked A6-All/B7-B19 (A6) and A19-A21/B41-B21 (A19) peptides.
Presentati of rHI by Thymic APCs. BALB/c TNCs, T-ROS, and DCs/M4s present HI to BALB/c-derived HI/ I-Ad-reactive T-cell hybrids and peripheral lymph node T cells (Fig. 3) . However, T-ROS present HI less efficiently than do DCs/M~s and TNCs. Addition of rHI to culture was Presentation of HII A6 and A19 Peptides by Thymic APCs. The I-Ad-bound HI A6 and A19 peptides on TNCs were acid-eluted in insufficient quantity (0.1 nM) to determine if they can be presented to T cells. Therefore, synthetic A6 and A19 peptides, which possess the same amino acid composition and disulfide bonds as the naturally processed ones, were used in APC assays. These peptides were not presented by either TNCs (Fig. 4 A and B) , T-ROS (Fig. 4 C and D) , DCs/Mos (Fig. 4 E and F (Fig. 4 A, C , and E) or lymph node T cells from HI-primed mice (Fig. 4 B, D, and F) (Fig. 5A) , T-ROS (Fig. SB) , and DCs/Mgs (Fig. 5C) MHC class II, similar competition assays were performed using fixed APCs. HI A6 inhibited the presentation of HI by fixed T-ROS (Fig. 6A ) and TA3 cells (Fig. 6B ) by 75% and 71%, respectively. A similar inhibition was observed with the HI A19 and positive control OVA-(323-336) peptides but not the Mb-(132-151), HIV Gp17-(65-80), and BI A-chain negative control peptides, suggesting that the A6, A19, and OVA peptides bind in the groove of I-Ad.
DISCUSSION
Thymic T-cell selection may result from TCR recognition of different peptide-self-MHC complexes on various thymic APCs (7), but evidence for the presence of such complexes on these APCs has not yet been found. We show that insulin, an extrathymic antigen, circulates rapidly to the thymus and is processed into predominantly different peptides by TNCs (mediate positive selection) and DCs/M~s (mediate negative selection). Qualitative and quantitative differences were detected in TNC and DC/M4 membrane-associated HI peptides. Only two of greater than eight major HI membraneassociated TNC peptides bound to MHC class II. Limitations in the sensitivity of peptide detection preclude us from excluding the presence of other MHC class II-bound HI peptides on TNCs and DCs/Mos. Nonetheless, it is interesting that only five hen egg lysozyme (HEL) peptides bind to I-Ak and four of them contain the dominant HEL-(52-61) T-cell epitope (3) . This agrees with the suggestion that peptides presented by MHC class II at a density sufficient to activate T cells may be of limited complexity for a given antigen (1, 2) . While TNCs, T-ROS, and DCs/M4s present HI to HI-specific T cells, the I-Ad-bound HI A6 and A19 peptides were detected only on TNCs. Thus, HI may be processed differently and/or to different extents in TNCs and DCs/Mos, and these APCs may vary in the HI peptide-MHC class II complexes they present to T cells. Fig. 5 . Ctrl, Control. in their structure that might allow some A-chain residues to extend beyond the groove.
If disulfide bond reduction mediates antigen processing of insulin in vivo, the presence of disulfide-linked HI peptides bound to MHC class II on TNCs suggests that this reduction occurs at the cell surface after the formation of peptide-MHC class II complexes. Removal of the proposed kink in the disulfide-linked peptide structure upon reduction might promote a better induced fit of the peptide in the MHC class II groove and enhanced T-cell receptor recognition. However, reduction ofdisulfide bonds in peptides A6 and A19 after they bound to MHC class II did not enable them to be presented to T cells. This lack of T-cell immunogenicity of A19 was expected since it is identical in sequence to its self-mouse insulin homolog. The inability of A6 to be presented may be due either to its lack of or weak immunogenicity. Although it consists of an immuhodominant A-chain loop containing T-cell epitope, it lacks some loop-flanking residues required for its immunogenicity (24, 25) . This peptide differs from its self-mouse insulin homolog only at residue B9 (20) , which may result in the absence or low frequency of A6-specific peripheral T cells.
T-cell unresponsiveness to HI A6 and A19 may arise from the striking structural similarity between the B7-B19 and B14-B21 B-chain components of these peptides and the B8-B18 and B10-B22 peptides demonstrated by Muir et al. (28) and H. Weiner (29) , respectively, to suppress the incidence of type I diabetes in nonobese diabetic mice after oral administration of HI. Oral administration of either HI A-chain or various A-chain peptides did not prevent diabetes onset. Thus, processed insulin B-chain linear peptides or heterodimeric disulfide-linked peptides that contain these linear B-chain fragments may elicit the T-cell unresponsiveness to HI observed here and the induction of oral tolerance to insulin and suppression of type I diabetes previously reported (27) .
Our observations illustrate the importance of examining the T-cell immunogenicity of MHC-bound peptides physiologically processed in vivo, since only a fraction of these peptides may be immunogenic and involved in positive T-cell selection. They may also explain why a nonimmunogenic peptide(s) of an antigen is bound to and cotransported with MHC class II molecules to the surface of a given APC in the thymus and/or periphery (i.e., to induce tolerance). Finally, they may identify naturally processed peptides of a given autoantigen (e.g., HI) that could prove efficacious in the prevention of an autoimmune disease.
